Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cell cycle G2-M checkpoint is a critical regulatory mechanism in eukaryotic cells that ensures the integrity of the genome before a cell enters mitosis (M phase). This checkpoint occurs at the transition between the G2 phase (the second gap phase) and M phase, serving as a quality control system to prevent cells with damaged or incompletely replicated DNA from proceeding into mitosis. The primary function is to detect DNA damage or incomplete DNA replication after S phase and halt cell cycle progression until these issues are resolved. If errors or damage are detected, signaling pathways activate repair mechanisms. If repair is unsuccessful, apoptosis may be triggered to prevent propagation of defective genetic material. Key components include Cyclin B-CDK1 complex, Wee1 and Myt1 kinases, Cdc25 phosphatase, ATM/ATR kinases, Chk1/Chk2 kinases, and p53 tumor suppressor protein. Loss of integrity in this pathway leads to genomic instability and cancer predisposition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell Cycle G2-M Checkpoint.